How HALO Slip Proved Costly For CinCor In AstraZeneca Talks
Buyout Price Slashed After Baxdrostat Fail
Hindsight is a wonderful thing but the saga of AstraZeneca's acquisition of CinCor is an eye-opener as SEC filings reveal that a $60 per share offer was rejected in September before a $26 bid won the day earlier this month.
